Risk Of Developing Liver Cancer After HCV Treatment

Thursday, December 29, 2016

This Army Vet Is Fighting Hep C With Big Pharma’s Help

This Army Vet Is Fighting Hep C With Big Pharma’s Help
by Doni Bloomfield
@DoniBloomfield
More stories by Doni Bloomfield
‎December‎ ‎29‎, ‎2016‎ ‎5‎:‎00‎ ‎AM‎ ‎EST

Burkett specializes in lining up testing and treatment for patients, and most of his work is funded by companies including Gilead Sciences Inc.AbbVie Inc. and Merck & Co. that have sold almost $50 billion of the new antivirals since they began hitting the market in 2013. Stiff competition has driven prices down and discounts up, and many insured patients have already been treated. That’s been bad news for the market leader, Gilead, which must increasingly find patients through the social service networks that target drug users and the poor. Many patients don’t even know they have the infection, which can take years to show symptoms.

“They are seeing patient volume declines even though there are 1 or 2 million patients out there,” said Michael Yee, an analyst with RBC Capital Markets. “They have to go out and find those 1 to 2 million.”
Continue reading...

No comments:

Post a Comment